Over recent decades, life expectancy has steadily increased across most developed societies. Yet the real challenge of our era is no longer simply to live longer, but to live better – with health, ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
New research on heart rate variability suggests that composure isn’t a personality trait. It’s a physiological skill the nervous system can train—one that may determine who thrives when the stakes are ...
Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...
Those of us who watch the Olympics as bystanders tend to smugly judge athletes for succumbing to pressure without understanding what we even mean by the term. The first thing to know about pressure is ...
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
Objectives We systemically reviewed the literature to assess how long-term testosterone suppressing gender-affirming hormone therapy influenced lean body mass (LBM), muscular area, muscular strength ...
Erika Rasure is globally-recognized as a leading consumer economics subject matter expert, researcher, and educator. She is a financial therapist and transformational coach, with a special interest in ...